Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26.8M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
5.98M
-
Shares change
-
+138K
-
Total reported value, excl. options
-
$20.9M
-
Value change
-
+$440K
-
Put/Call ratio
-
0.03
-
Number of buys
-
14
-
Number of sells
-
-11
-
Price
-
$3.49
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q2 2023
41 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.98M shares
of 26.8M outstanding shares and own 22.26% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.29M shares), VANGUARD GROUP INC (976K shares), Westside Investment Management, Inc. (519K shares), Acuitas Investments, LLC (510K shares), PARADIGM CAPITAL MANAGEMENT INC/NY (300K shares), BlackRock Inc. (298K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (241K shares), GEODE CAPITAL MANAGEMENT, LLC (210K shares), AWM Investment Company, Inc. (159K shares), and Bank of New York Mellon Corp (79.4K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.